Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: The end TB trial

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S8-S12

  Cellamare, M ^a   Milstein, M ^b,c   Ventz, S ^d,e   Baudin, E ^f   Trippa, L ^e   Mitnick, C D ^b,g,h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g PARTNERS IN HEALTH   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bayesian adaptive randomization; Clinical trial; MDR TB

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADAPTIVE CLINICAL TRIAL; ARTICLE; BAYES THEOREM; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIMULATION; TREATMENT RESPONSE; BIOASSAY; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; METHODOLOGY; SAMPLE SIZE;

ANTITUBERCULAR AGENTS; BAYES THEOREM; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85016093947     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0066     Document Type: Article

References (27)

1. Nunn A J, Rusen I D, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014; 15: 353.
2. Piubello A, Harouna S H, Souleymane M B, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
3. Aung K J, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
4. Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
5. Kuaban C, Noeske J, Rieder H L, Äit-Khaled N, Abena Foe J L, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-524.
6. World Health Organization. Global tuberculosis report, 2015. WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO, 2015.
7. Diacon A H, Pym A, Grobusch M P, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
8. Diacon A H, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
9. Gler M T, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
10. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
11. ClinicalTrials.gov. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis (NCT01424670). Bethesda, MD, USA: National Institutes of Health, 2015. ClinicalTrials.gov (updated September 2015).
12. Thall P F, Wathen J K. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007; 43: 859-866.
13. Berry D A, Eick S G. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 1995; 14: 231-246.
14. World Health Organization. Guildelines for the programmatic management of multidrug-resistant tuberculosis. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
15. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis interim policy guidance. WHO/HTM/TB2014.23. Geneva, Switzerland: WHO, 2014.
16. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis interim policy guidance. WHO/HTM/TB/2013.6 Geneva, Switzerland: WHO, 2013.
17. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis; 2016 update. WHO/HTM/TB/2016.04. Geneva, Switzerland: WHO, 2016.
18. Alexander B M, Trippa L. Progression-free survival: too much risk, not enough reward? Neurooncology 2014; 16: 615-616.
19. Trippa L, Wen P Y, Parmigiani G, Berry D A, Alexander B M. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neurooncology 2015; 17: 1106-1113.
20. Ventz S, Trippa L. Bayesian designs and the control of frequentist characteristics: a practical solution. Biometrics 2015; 71: 218-226.
21. Bowden J, Trippa L. Unbiased estimation for response adaptive clinical trials. Stat Methods Med Res 2015; pii: 0962280215597716.
22. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLOS Med 2012; 9: e1001300.
23. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
24. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
25. Wason J M, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med 2014; 33: 2206-2221.
26. Trippa L, Lee E Q, Wen P Y, et al. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 2012; 30: 3258-3263.
27. Diacon A H, Donald P R, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.